| Website | venture.burrillan... |
| Phone | (415) 591-5400 |
| Employees | |
| Description | Life Sciences VC |
| Total | $425M |
| Burrill Capital Fund IV, 12/11 | $300M |
| Burrill Brazil Fund I, 1/12 | $125M |
Burrill & Company invests in life science companies whose technologies and products are applicable across a wide range of life science sub-sectors: human healthcare therapeutics and diagnostics/devices; health/wellness; agricultural biotechnology; biofuels, and industrial biotechnology (biomaterials/bioprocesses).
| Company | Date | Round | Size | Participants |
| Yaupon Therapeutics | 8/11 | Series D | $14.4M | 4 |
| AliveCor | 8/11 | Series A | $3M | 3 |
| NewBridge Pharmaceuticals | 9/10 | Series B | $12M | 2 |
| FerroKin Biosciences | 6/10 | Series B | $12M | 5 |
| Endocyte | 1/10 | Series C | $26M | 5 |
| PrimeraDx | 10/09 | Series C | $20M | 6 |
| XDx | 10/09 | Unattributed | $14.4M | 7 |
| XDx | 8/09 | Series F | $14.4M | 8 |
| HCL CleanTech | 6/09 | Series A | $5.5M | 2 |
| Aerovance | 4/09 | Unattributed | $38M | 8 |
| Catalyst Biosciences | 12/08 | Series C | $40M | 7 |
| Gevo | 5/08 | Series C | $17M | 4 |
| Osprey Pharmaceuticals USA | 5/08 | Series A | $11M | 6 |
| NanoVasc | 3/08 | Series A | $4.7M | 2 |
| Light Sciences Oncology | 7/07 | Series B | $30M | 5 |
| Aerovance | 3/07 | Series C | $60M | 6 |
| diaDexus | 1/07 | Series E | $40M | 7 |
| Neurotech | 11/06 | Series B | $35M | 12 |
| Sciona | 4/06 | Series C | $9.9M | 5 |
| Chromatin | 4/06 | Unattributed | $1.6M | 4 |
| Catalyst Biosciences | 2/06 | Series B | $30M | 6 |
| Adlyfe | 1/06 | Series A | $3.3M | 2 |
| XDx | 1/06 | Unattributed | $26.5M | 7 |
| Chlorogen | 8/05 | Series B | $6M | 4 |